- Home
- QNST vs AKBA Comparison
QNST vs AKBA Comparison
Compare QNST & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNST
- AKBA
- Stock Information
- Founded
- QNST 1999
- AKBA 2007
- Country
- QNST United States
- AKBA United States
- Employees
- QNST N/A
- AKBA N/A
- Industry
- QNST Business Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- QNST Consumer Discretionary
- AKBA Health Care
- Exchange
- QNST Nasdaq
- AKBA Nasdaq
- Market Cap
- QNST 923.2M
- AKBA 861.7M
- IPO Year
- QNST 2010
- AKBA 2014
- Fundamental
- Price
- QNST $16.18
- AKBA $2.92
- Analyst Decision
- QNST Buy
- AKBA Strong Buy
- Analyst Count
- QNST 6
- AKBA 5
- Target Price
- QNST $27.33
- AKBA $6.90
- AVG Volume (30 Days)
- QNST 561.6K
- AKBA 3.8M
- Earning Date
- QNST 11-03-2025
- AKBA 11-06-2025
- Dividend Yield
- QNST N/A
- AKBA N/A
- EPS Growth
- QNST N/A
- AKBA N/A
- EPS
- QNST 0.08
- AKBA N/A
- Revenue
- QNST $1,093,711,000.00
- AKBA $203,733,000.00
- Revenue This Year
- QNST $10.72
- AKBA $38.23
- Revenue Next Year
- QNST $9.66
- AKBA $38.17
- P/E Ratio
- QNST $201.75
- AKBA N/A
- Revenue Growth
- QNST 78.27
- AKBA 16.75
- 52 Week Low
- QNST $14.27
- AKBA $1.24
- 52 Week High
- QNST $26.27
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- QNST 56.23
- AKBA 39.09
- Support Level
- QNST $15.64
- AKBA $2.91
- Resistance Level
- QNST $16.36
- AKBA $3.15
- Average True Range (ATR)
- QNST 0.45
- AKBA 0.14
- MACD
- QNST 0.09
- AKBA 0.00
- Stochastic Oscillator
- QNST 77.62
- AKBA 6.25
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.